Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesChemistry ProceduresCPT cpt-84233-estrogen-receptor-assay-tumor-tissue
    Ask Trek AI about this page

    CPT 84233: Estrogen Receptor Assay on Tumor Tissue

    CPT code 84233 describes an estrogen receptor assay (ERA) performed by a laboratory analyst on tumor tissue—commonly breast tissue—to detect estrogen receptor proteins that influence cancer treatment selection; this is a laboratory immunoassay service typically performed in an anatomic pathology or clinical laboratory setting using surgically obtained or biopsy tissue specimens.

    For related coverage guidance, see recent payer policy updates: Diabetic Supplies, Radiofrequency Ablation for Thyroid Nodules, Continuous Glucose Monitoring and Insulin Delivery for Managing Diabetes (for Idaho Only).

    Customize your policy alerts

    Sign up for cpt 84233 policy alerts

    Get alerted when payer policies referencing 84233 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 58-year-old female presents after a core needle biopsy of a suspicious breast mass identified on mammography and ultrasound. The pathology report confirms invasive ductal carcinoma; the oncology team requests an estrogen receptor assay to determine tumor hormone receptor status and guide systemic therapy decisions. The specimen is submitted to the pathology laboratory; a histotechnologist prepares formalin-fixed, paraffin-embedded tissue sections and the lab analyst performs an estrogen receptor assay (84233) using immunohistochemistry or other validated assay methods. Results are interpreted by a pathologist and entered into the pathology report; positive estrogen receptor status supports endocrine therapy, while negative status influences chemotherapy planning. Typical workflow steps include specimen accessioning, tissue processing, assay performance, pathologist interpretation, and reporting. Typical site of service is a hospital outpatient laboratory or independent pathology laboratory associated with a breast surgery or oncology clinic.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    88342Immunohistochemistry or immunocytochemistry, per single antibody stain, including reagent usage and interpretationOften used alongside or as an alternative method to determine estrogen receptor status via IHC staining on tumor tissue
    88360Morphometric analysis, tumor immunohistochemistry; quantitative image analysisMay be used when quantitative measurement of receptor staining is required for report reproducibility
    88305Surgical pathology, gross and microscopic examination of tissue, commonly used for biopsy specimensPerformed on the breast core biopsy that yields tissue subsequently tested with 84233
    84153Estradiol; quantitativeSerum estradiol testing may be ordered in the broader endocrine workup but is not a substitute for tumor ER testing
    85025Blood count; automated CBC with differentialCommon laboratory test during surgical or oncology workups surrounding the biopsy or treatment planning
    88341Immunohistochemistry or immunocytochemistry, first single antibody stain (technical component)Technical counterpart when billing split professional/technical components for IHC testing related to receptor assays

    Related Modifiers

    7 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207P00000X
    207Q00000X
    207K00000X
    207L00000X
    207RH0000X
    1835P1300X
    363LS0200X
    207VC0200X

    Related ICD-10-CM Codes

    26 rows

    ICD-10-CM CodeDescription
    C50.011Malignant neoplasm of nipple and areola, right female breast
    C50.012Malignant neoplasm of nipple and areola, left female breast
    C50.111Malignant neoplasm of central portion of right female breast
    C50.112Malignant neoplasm of central portion of left female breast
    C50.211Malignant neoplasm of upper-inner quadrant of right female breast
    C50.212Malignant neoplasm of upper-inner quadrant of left female breast
    C50.311Malignant neoplasm of lower-inner quadrant of right female breast
    C50.312Malignant neoplasm of lower-inner quadrant of left female breast
    C50.411Malignant neoplasm of upper-outer quadrant of right female breast
    C50.412Malignant neoplasm of upper-outer quadrant of left female breast

    Showing 1–10 of 26

    Related Payer Policy Updates

    Specialty: Endocrinology1 / 3

    10 rows

    PolicyPayerEffective Date
    Diabetic SuppliesCigna2026-10-15
    Radiofrequency Ablation for Thyroid NodulesCigna2026-10-15
    Continuous Glucose Monitoring and Insulin Delivery for Managing Diabetes (for Idaho Only)UnitedHealthcare2026-10-01
    Continuous Glucose Monitoring and Insulin Delivery for Managing Diabetes (for Indiana Only)UnitedHealthcare2026-10-01
    Tzield (teplizumab-mzwv) CoverageUnitedHealthcare2026-10-01
    Medical Necessity Guidelines Insulin PumpsMass General Brigham Health Plan2026-10-01
    Medical Necessity Guidelines: Continuous Glucose MonitorsMass General Brigham Health Plan2026-10-01
    Continuous Glucose MonitoringAmbetter Nevada2026-10-01
    Salivary Hormone TestingOscar Health2026-10-01
    Bone Turnover Markers TestingOscar Health2026-10-01

    Related Codes

    CPT-82009-KETONE-BODIES-QUALITATIVE-TEST

    CPT 82009: Qualitative Ketone Bodies Test

    CPT-82010-QUANTITATIVE-KETONE-BODIES-ASSAY-SERUM-PLASMA

    CPT 82010: Quantitative Ketone Bodies in Serum or Plasma

    CPT-82013-ACETYLCHOLINESTERASE-QUANTITATIVE-ASSAY

    CPT 82013: Quantitative Acetylcholinesterase (Acetylhydrolase) Assay

    CPT-82016-QUALITATIVE-ACYLCARNITINES-METABOLIC-SCREEN

    CPT 82016: Qualitative Acylcarnitines, Plasma/Serum/Urine

    CPT-82017-QUANTITATIVE-ACYLCARNITINE-ANALYSIS

    CPT 82017: Quantitative Acylcarnitine Analysis

    CPT-82024-QUANTITATIVE-CORTICOTROPIN-ACTH-ASSAY

    CPT 82024: Adrenocorticotropic Hormone (ACTH) Quantitative Assay

    CPT-82030-QUANTITATIVE-CAMP-PLASMA-URINE-ASSAY

    CPT 82030: Quantitative cyclic AMP assay on plasma or urine

    CPT-82040-QUANTITATIVE-ALBUMIN-MEASUREMENT

    CPT 82040: Quantitative Albumin Measurement

    CPT-82042-QUANTITATIVE-ALBUMIN-NONBLOOD-FLUID

    CPT 82042: Albumin Quantitation in Non-Blood Body Fluid

    CPT-82043-URINE-ALBUMIN-QUANTITATION-KIDNEY-DISEASE

    CPT 82043: Urine Albumin Quantitative Assay

    Showing 1–10 of 411

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.